BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Pharma Research

NS Pharma Parent Nippon Shinyaku Secures Global Option Rights to Develop Elixirgen's DMD Therapy EXG-7001

NS Pharma, Inc. (NS Pharma; Headquarters, Paramus, NJ; President, Yukiteru Sugiyama) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon S...

June 30, 2026 | News

Metabolon Delivers Landmark Metabolomics Dataset to Advance Rare Disease Research with Genomics England

Metabolon, Inc., the global leader in metabolomics solutions advancing life science research, diagnostics, therapeutics, and precision medicine, announced ...

June 26, 2026 | News

Abbisko Therapeutics Expands Strategic Alliance with Lilly in Multi-Target Drug Discovery Deal Worth Up to $1.9 Billion

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collab...

June 25, 2026 | News

Mabwell Secures China Clinical Trial Approval for First-in-Class LILRB4/CD3 Bispecific T-Cell Engager in Blood Cancers

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical P...

June 25, 2026 | News

DoH Abu Dhabi and Sanofi Deepen Partnership to Build Next-Generation Vaccine Innovation Hub

The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines...

June 24, 2026 | News

After the Drug Substance, the Real Squeeze: APAC's Aseptic Fill-Finish Gap

For most of the last decade, the anxiety in Asia-Pacific biomanufacturing pointed upstream. The conversation was about bioreactor volume — how many t...

June 22, 2026 | Analysis

Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast in Lower-Risk Myelodysplastic Syndromes

Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026 Ha...

June 17, 2026 | News

Agility or Corner-Cutting? Asia's Accelerated-Approval Gamble

On 1 April 2026, Japan's Pharmaceuticals and Medical Devices Agency did something no other major medicines regulator had done before it: from that date, ev...

June 17, 2026 | Analysis

Rejuvenate Bio and Merck Animal Health Join Forces on Novel Animal Health Gene Therapy Programme

-- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate...

June 15, 2026 | News

Akeso Expands Immunology Franchise with Approval of Gumokimab for Psoriasis

Akeso, Inc. announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-devel...

June 15, 2026 | News

Simcere and Stanford Medicine Partner to Advance First-in-Class Therapy for Idiopathic Pulmonary Fibrosis

Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory stu...

June 15, 2026 | News

Mabwell's First In Class Autoimmune Antibody 9MW5211 Wins China Clinical Trial Approval for IBD

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently...

June 08, 2026 | News

CAS Brings Trusted Scientific Intelligence Directly Into R&D Workflows Through New Connections Framework

CAS, a division of the American Chemical Society specializing in scientific knowledge management, announced CAS Connections, a new integration framework th...

June 05, 2026 | News

Advancing NAD Biomarkers From Research Discovery To Clinical Reality

As interest in metabolic health, longevity science, and precision medicine continues to grow, the ability to accurately measure biological markers linked t...

June 03, 2026 | Interview

Stay Connected